Provided by Tiger Fintech (Singapore) Pte. Ltd.

Disc Medicine

52.24
-0.9900-1.86%
Pre-market: 51.22-1.0200-1.95%04:01 EDT
Volume:1.08M
Turnover:56.92M
Market Cap:1.81B
PE:-13.19
High:54.01
Open:52.87
Low:52.06
Close:53.23
Loading ...

Wedbush Raises Price Target on Disc Medicine to $90 From $83, Keeps Outperform Rating

MT Newswires Live
·
21 Jan

Disc Medicine announces feedback from Type C meeting with FDA

TIPRANKS
·
21 Jan

Disc Medicine Announces Successful Type C Meeting With FDA for Bitopertin in Erythropoietic Protoporphyria (Epp) and Shares Plans for Nda Submission

THOMSON REUTERS
·
21 Jan

Disc Medicine Inc - Planning to Submit Nda Under Accelerated Approval Pathway in H2 2025

THOMSON REUTERS
·
21 Jan

Disc Medicine : Plans to Initiate Apollo Trial by Mid-2025 and Will Include Sites in US, Canada, Europe, and Australia

THOMSON REUTERS
·
21 Jan

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

GlobeNewswire
·
21 Jan

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

GlobeNewswire
·
21 Jan

Disc Medicine Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
18 Jan

Press Release: Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

Dow Jones
·
18 Jan

BUZZ-Disc Medicine falls after flagging 'material weakness'

Reuters
·
11 Jan

BRIEF-Disc Medicine Expects To Report Material Weakness in Annual Report

Reuters
·
10 Jan

Disc Medicine Highlights 2025 Strategy and Financial Updates

TIPRANKS
·
10 Jan

Disc Medicine outlines recent pipeline, priorities for 2025

TIPRANKS
·
10 Jan

Disc Medicine:Expects to Report Material Weakness in Internal Control Over Financial Reporting in Annual Report on Form 10-K for Yt Ended Dec 31, 2024

THOMSON REUTERS
·
10 Jan

Disc Medicine : Material Weakness Is Related to Lack of Design and Maintenance of Effective Itgc Over Certain Key Financial It Systems

THOMSON REUTERS
·
10 Jan

Disc Medicine Inc: to Date, Co Has Not Identified Any Misstatements in Its Financial Statements

THOMSON REUTERS
·
10 Jan